Myelodysplastic Syndromes Clinical Trials in Palo Alto, California

4 studies are recruiting for myelodysplastic syndromes in Palo Alto, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

    The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT). Post-HCT tacrolimus is given to prevent graft-vs-host-disease (GVHD), but with the use of post-transplant cyclophosphamide (PTCy), the mode…

    Stage
    Phase 1
    Ages
    18 to 80
    Site
    Stanford University, Palo Alto, California
    Run by
    Stanford University

    See if you can join NCT07302776 on ClinicalTrials.gov

  2. Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

    The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

    Stage
    Phase 1
    Ages
    18 to 70
    Site
    Stanford University, Palo Alto, California
    Run by
    Stanford University

    See if you can join NCT06551584 on ClinicalTrials.gov

  3. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Stanford University, Palo Alto, California
    Locations
    104 in total
    Run by
    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov

  4. A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

    Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the sa…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Stanford Cancer Center, Palo Alto, California
    Locations
    13 in total
    Run by
    BlossomHill Therapeutics

    See if you can join NCT06501196 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.